Investors take note—big pharma has no physical assets to develop drugs, nor the skills required

Hedley's interview with TrialSite News

Investors hold the key to stopping big pharma antics

There is one sure way to get the attention of big pharma—investors unhappy with the performance of their hard-earned cash injections (excuse the pun!).

The previous post below should have given you a flavour of the risks and potholes that scatter the big pharma landscape.

Big pharma’s 40-year love affair with outsourcing everything must end

My TrialSite News interview wit…